Paul Tudor Jones’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-45,776
| Closed | -$3.67M | – | 3898 |
|
|
2025
Q4 | $3.67M | Buy |
+45,776
| New | +$3.08M | 0.01% | 1361 |
|
|
2025
Q2 | – | Sell |
-19,598
| Closed | -$1.25M | – | 3446 |
|
|
2025
Q1 | $1.25M | Buy |
+19,598
| New | +$1.33M | ﹤0.01% | 1671 |
|
|
2024
Q4 | – | Sell |
-3,065
| Closed | -$246K | – | 3213 |
|
|
2024
Q3 | $246K | Buy |
+3,065
| New | +$248K | ﹤0.01% | 2418 |
|
|
2023
Q2 | – | Sell |
-16,353
| Closed | -$1.35M | – | 2636 |
|
|
2023
Q1 | $1.35M | Buy |
+16,353
| New | +$1.32M | 0.02% | 1013 |
|
|
2020
Q1 | – | Sell |
-6,886
| Closed | -$791K | – | 1163 |
|
|
2019
Q4 | $791K | Buy |
6,886
+3,576
| +108% | +$433K | 0.04% | 579 |
|
|
2019
Q3 | $418K | Buy |
+3,310
| New | +$420K | 0.01% | 767 |
|
|
2019
Q2 | – | Sell |
-27,729
| Closed | -$2.43M | – | 1190 |
|
|
2019
Q1 | $2.43M | Buy |
27,729
+14,886
| +116% | +$1.35M | 0.1% | 227 |
|
|
2018
Q4 | $1.28M | Buy |
12,843
+6,206
| +94% | +$652K | 0.03% | 313 |
|
|
2018
Q3 | $760K | Sell |
6,637
-28,066
| -81% | -$2.91M | 0.02% | 549 |
|
|
2018
Q2 | $3.11M | Buy |
34,703
+18,456
| +114% | +$1.56M | 0.11% | 151 |
|
|
2018
Q1 | $1.19M | Buy |
16,247
+2,210
| +16% | +$152K | 0.04% | 279 |
|
|
2017
Q4 | $815K | Sell |
14,037
-8,622
| -38% | -$454K | 0.02% | 416 |
|
|
2017
Q3 | $1.02M | Sell |
22,659
-5,467
| -19% | -$227K | 0.03% | 386 |
|
|
2017
Q2 | $1.11M | Buy |
28,126
+143
| +0.5% | +$5.87K | 0.03% | 311 |
|
|
2017
Q1 | $1.14M | Buy |
27,983
+15,737
| +129% | +$615K | 0.03% | 337 |
|
|
2016
Q4 | $492K | Buy |
+12,246
| New | +$462K | 0.01% | 733 |
|
|
2016
Q3 | – | Sell |
-16,898
| Closed | -$490K | – | 1544 |
|
|
2016
Q2 | $490K | Buy |
+16,898
| New | +$511K | 0.01% | 846 |
|
|
2014
Q3 | – | Sell |
-10,100
| Closed | -$356K | – | 1401 |
|
|
2014
Q2 | $356K | Sell |
10,100
-19,418
| -66% | -$649K | 0.01% | 747 |
|
|
2014
Q1 | $962K | Buy |
29,518
+23,618
| +400% | +$903K | 0.04% | 205 |
|
|
2013
Q4 | $249K | Sell |
5,900
-2,800
| -32% | -$115K | 0.01% | 989 |
|
|
2013
Q3 | $347K | Sell |
8,700
-1,100
| -11% | -$46.2K | 0.01% | 520 |
|
|
2013
Q2 | $405K | Buy |
+9,800
| New | +$397K | 0.03% | 425 |
|
Other funds holding HAE
RRAM
Paul Tudor Jones's HAE Position: Q1 2026 in Review
Paul Tudor Jones sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 45,776 shares — an estimated $3.67M sold.
Paul Tudor Jones first reported a position in HAE in Q2 2013 and held it in 22 quarters. The position peaked at $3.67M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Paul Tudor Jones reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
- Paul Tudor Jones sold 45,776 Haemonetics shares in Q1 2026, an estimated $3.67M.
- Paul Tudor Jones first reported a position in Haemonetics in Q2 2013 and held it in 22 quarters.
- Paul Tudor Jones's Haemonetics position peaked at $3.67M in Q4 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.